IFNAR2/IFN complex

US6372207B1 · kind B1 · utility

Assignee

• APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

Inventors

• Mark Tepper · Canton, US
• Mark Cunningham · Kennett Square, US
• David Sherris · Brookline, US
• Nabil El Tayar · Milton, US
• Sean D. McKenna · Duxbury, US

Key dates

• Filing date: Dec 18, 1998
• Grant date: Apr 16, 2002
• Expiry date: Dec 18, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The in vivo effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon &agr;/&bgr; receptor (IFNAR). Such a complex also improves the stability of the IFN and enhances the potency of the IFN. The complex may be a non-covalent complex or one in which the IFN and the IFNAR are bound by a covalent bond or a peptide. When bound by a peptide bond in the form of a fusion protein, the IFN may be separated from the IFNAR by means of a peptide linker. Such a fusion protein may be produced by recombinant DNA technology. Storing IFN in the form of such a complex improves the storage life of the IFN and permits storage under milder conditions than would otherwise be possible.